NEW DRUGS FOR THE TREATMENT OF CANCER
PharmaEngine
We Race With You
DISCOVER MORE
CANCER TREATMENT PRODUCTS
ONIVYDE
A Revolutionary Durg
DISCOVER ONIVYDE
History<br> &<br> Milestones<br>
History
&
Milestones
Onivyde
Onivyde

Positive Topline Results from Phase III NAPOLI-3 trial of ONIVYDE® regimen (NALIRIFOX) as a first-line treatment for previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)

PharmaEngine, Inc. Exercised Option for a Worldwide Exclusive License Agreement to Sentinel Oncology Limited’s CHK1 inhibitor

The Results from Phase III RESILIENT trial of irinotecan liposome injection (ONIVYDE®) as a second-line monotherapy treatment for small cell lung cancer (2L SCLC)
PEP07
R&D Pipeline
Events & Presentations
Organization
Our Partners
Contact Us
© 2020 PharmaEngine Inc.
Go To Top